Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7201 - 7225 of 8498 in total
Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.
Investigational
Matched Description: … Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, …
Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac Vein Obstruction.
Investigational
Matched Description: … Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac …
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
Investigational
Matched Description: … Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of
Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).
Investigational
Matched Description: … Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid …
Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
Investigational
Matched Description: … Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed …
(S)-Propafenone is under investigation in clinical trial NCT02710669 (New Formulations of Propafenone to Treat Atrial Fibrillation).
Investigational
Matched Description: … (S)-Propafenone is under investigation in clinical trial NCT02710669 (New Formulations of Propafenone …
NSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).
Investigational
Matched Description: … NSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder …
TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.
Investigational
Matched Description: … TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157] …
Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.
Investigational
Matched Description: … Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers …
MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.
Investigational
Matched Description: … MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins. …
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
Matched Description: … BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis …
ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
Investigational
Matched Description: … ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing …
RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).
Investigational
Matched Description: … RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase …
PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.
Investigational
Matched Description: … PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme …
Peresolimab is under investigation in clinical trial NCT04634253 (A Study of LY3462817 in Participants With Rheumatoid Arthritis).
Investigational
Matched Description: … Peresolimab is under investigation in clinical trial NCT04634253 (A Study of LY3462817 in Participants …
Camonsertib is under investigation in clinical trial NCT04497116 (Study of RP-3500, Camonsertib, in Advanced Solid Tumors).
Investigational
Matched Description: … Camonsertib is under investigation in clinical trial NCT04497116 (Study of RP-3500, Camonsertib, in Advanced …
Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).
Investigational
Matched Description: … Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for …
Ponsegromab is under investigation in clinical trial NCT05492500 (A Study of Ponsegromab in People With Heart Failure).
Investigational
Matched Description: … Ponsegromab is under investigation in clinical trial NCT05492500 (A Study of Ponsegromab in People With …
Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).
Investigational
Matched Description: … Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug …
NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability. It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and...
Investigational
Matched Description: … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic ... glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been ... [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of
Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. In clinical trials, it has shown significant efficacy and safety compared to a placebo. The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. Despite...
Investigational
Matched Description: … Despite its promising results, the long-term safety of rocatinlimab requires further investigation, as ... Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe ... Additionally, the diverse genetic backgrounds of patients may influence the drug’s effectiveness and …
4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts...
Experimental
Illicit
Matched Description: … of the many byproducts of formestane metabolism. ... Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one …
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Investigational
Matched Description: … synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of
is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
Investigational
Matched Description: … The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent …
An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).
Experimental
Matched Description: … has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of
Displaying drugs 7201 - 7225 of 8498 in total